Neues zur Therapie des Mammakarzinoms und der gynäkologischen Karzinome

Zusammenfassung

Die dosis-dichte Chemotherapie (DDC) und die Hochdosischemotherapie sowohl adjuvant als auch in der primären Therapie des Mammakarzinoms waren eines der Hauptthemen des diesjährigen Meetings. Studien zu den Fragestellungen GnRH nach Chemotherapie bei prämenopausalen Patientinnen, wie gut sind die Taxane in der adjuvanten und primären Chemotherapie in welchem Setting, wurden vorgestellt. Ein weiteres Brennthema war die optimale Screeningmethode bei high-risk-Frauen. Zum Thema Ovarialkarzinom wurden Daten sowohl zur Optimierung der Primär- als auch der Rezidivtherapie vorgestellt. Zur Therapie des Endometriumkarzinoms als auch des Zervixkarzinoms gab es wichtige Beiträge zur Primärtherapie und den Stellenwert der optimalen Strahlentherapie.

Abstract

Dose-dense chemotherapy and high dose chemotherapy have been issued in the adjuvant and primary therapy of breast cancer. Should we use GnRH analogues after chemotherapy in premenopausal women who have not become amenorrheic through chemotherapy? How important are the taxanes in the primary and adjuvant treatment of breast cancer? The optimal screening method for women at high-risk for breast cancer was addressed as one of the most important topics. Primary and recurrent ovarian cancer therapy needs to be improved further. The optimal primary therapy for endometrial cancer and cervical cancer with radiotherapy and/or chemotherapy was another addressed issue.

Mammakarzinom - Ovarialkarzinom - Endometriumkarzinom - Zervixkarzinom - Frauen mit erhöhtem Brustkrebs-Risiko

Breast cancer - ovarian cancer - endometrial cancer - cervical cancer - women at high-risk for breast cancer

Literatur

• 1 Alba E. et al .Multicenter phase-III randomized trial comparing sequential vesus concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer. GEICAM 9903 Study Proc ASCO 2003; abstr 27
• 2 Basser R. et al .Randomized trial comparing up-front, multicycle dose intensive chemotherapy versus standard dose chemotherapy in women with high-risk stage 2 of 3 breast cancer. First results from IBCSG Trial 15-95. Proc ASCO 2003; abstr 20
• 3 Blohmer J. et al .6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO intergroup study: Sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high-risk cervical cancer. Proc ASCO 2003; abstr 1798
• 4 Davidson N. et al .Chemohormonal therapy in premenopausal node-positive receptor-positive breast cancer: An Eastern Cooperative Oncology Group phase-III intergroup trial. (E5188, INT 0101) Proc ASCO 2003; 15
• 5 Eiermann W. et al .European kooperative trial in operable breast cancer ECTO: No increased risk of local breast tumor recurrence as first and only event after primary breast cancer. Proc ASCO 2003; abstr 37
• 6 Gonzalez Martin A. et al .Randomised phase-II-study of carboplatin (C) versus paclitaxel-carboplatin (C) in platinum-sensitive recurrent advanced ovarian carcinoma with assessment of quality of life. A GEICO study
• 7 Henderson I C. et al . Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.  J Clin Oncol. 2003;  21 976-983
• 8 Kriege M. et al .MRI screening for breast cancer in women with high familial and genetic risk: First results of the Dutch MRI screening study (MRISC). Proc ASCO 2003; abstr 5
• 9 Kuhl C. et al .Surveillance of “high-risk” women with proven or suspected familiar (hereditary) breast cancer: First mid-term results of a multi- modality clinical screening trial. Proc ASCO 2003; abstr 4
• 10 Ledermann J A. on behalf of ICON and AGO .Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum- based chemotherapy in the treatment of relapsed ovarian cancer. PROC ASCO 2002; abstr 1794
• 11 Mamounas E. et al .Paclitaxel following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node- positive breast cancer: Results from NSABP-B28. Proc ASCO 2003; abstr 12
• 12 von Minckwitz G. et al .Primary chemotherapy adapted on in-vivo-chemosensitivity in patients with primary breast cancer. The pilot Gepratrio-study. Proc. ASCO 2003; abstr 85
• 13 Muss H B. et al .Older women with node positive breast cancer get similar benefits from adjuvant chemotherapy as younger patients. The Cancer and Leukemia Group B (CALGB) Proc ASCO 2003; abstr 11
• 14 Nitz U. et al .Tandem high-dose chemotherapy versus dose-dense conventional chemotherapy for patients with high risk breast cancer: Interim results from a multicenter phase-III-trial. Proc ASCO 2003; abstr 3344
• 15 O' Shaughnessy J. et al .Gemcitabine plus paclitaxel versus paclitaxel as first-line treatment for anthracycline pre-treated metastatic breast cancer: Interim analyses results of a global phase-III-study. Proc ASCO 2003; abstr 25
• 16 Patchell A. A randomized trial of direct decompressive surgical resection in the treatment of spinal cord compression caused by metastasis. Proc ASCO 2003; abstr 2
• 17 Pfisterer J. et al .Paclitaxel/Carboplatin vs. paclitaxel/carboplatin followed by topotecan in first-line treatment of ovarian cancer FIGO stages II b-IV. Interim Results of a gynecologic cancer intergroup phase-III-trial of the AGO Ovarian Cancer Study Group and GINECO. Proc ASCO 2003; abstr 1793
• 18 Pignata S. et al .Topotecan vs. nihil after response to carboplatin and paclitaxel in advanced ovarian cancer. Early results of the MITO-1-study. Proc ASCO 2003; abstr 1791
• 19 Rodenhuis S. et al .High-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in high-risk breast cancer. Proc ASCO 2003; abstr 21
• 20 Scarfone G. et al .A multicenter, randomized, phase-III-study comoparing paclitaxel/carboplatin(PC) versus topotecan/paclitaxel/carboplatiian cancer. Proc ASCO 2003; abstr 1807
• 21 Schmalfeldt B. et al .Paclitaxel, carboplatin and gemcitabine triplet in previously untreated patients with epithelian ovarian cancer: Preliminary results of an AGO Ovarian cancer study group phase-II-trial. Proc ASCO 2003; abstr 1806
• 22 Tallman M. et al .Phase-III-study of conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem cell transplantation inf patients with stage II and III breast cancer at high risk of recurrence (INT 0121). Proc ASCO 2003; abstr 19
• 23 Untch M. et al .Negative steroid receptor are a good predictor for response to preoperative chemotherapy in breast cancer - results of a randomised trial. Proc ASCO 2003; abstr 35
• 24 Watkins-Bruner D. et al .Quality of life trade off to incremental gain in survival in Gynecology Oncology Group protocoll 122: Whole abdominal irradiation vs. doxorubicin-platinum chemotherapy in advanced endometrial cancer. Proc ASCO 2003; abstr 1803
• 25 Zielinski C. et al .Gemcitabine/epirubicin/paclitaxel (GET) vs. 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer. Proc ASCO 2003; abstr 26